ReviewTherapeutic advances in infectious disease
Infectious complications of CAR T-cell therapy: a clinical update.
Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.Blood advances · 2025Pooled it
- Identification and Characterization of Patient Populations at High Risk for Clostridioides difficile Infection (CDI): A Narrative Review.Infectious diseases and therapy · 2026Review
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Open forum infectious diseases · 2026Article
- Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Host Transcriptomics and Culture-Independent Testing for the Management of Febrile Neutropenia: Data From an Observational Study Conducted in a Bone Marrow Transplant Unit.European journal of haematology · 2026Observational
- A novel mannan-specific chimeric antigen receptor M-CAR redirects T cells to interact withBioengineered · 2025Article
- Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.Cancers · 2025Review
- Management ofEClinicalMedicine · 2025Review
- Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma.Blood advances · 2025Article
- Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.BMC infectious diseases · 2025Article
- Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.Drug safety · 2025Review
- Article
- Progressive Multifocal Leukoencephalopathy in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Case Study.Journal of the advanced practitioner in oncology · 2025Article
- Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis.Blood advances · 2025Article
- Proposed observational study protocol for early differentiation of cytokine release syndrome and sepsis in CAR-T recipients with haematological malignancies using the IL-6/PCT ratio: the DRACARYS study.Frontiers in oncology · 2025Article
- Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.Current pharmaceutical design · 2025Review
- Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.Therapeutic advances in hematology · 2025Article
- Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary treatment modality used to treat haematological malignancies. Lymphocytes are engineered to produce CARs directed towards tumour cell antigens. Clinical trials have demonstrated impressive malignancy-related outcomes. Unfortunately, numerous off-target effects can cause toxicity-related adverse events in this population, the main being cytokine release syndrome and immune effector cell neurotoxicity syndrome. This causes significant patient morbidity and poor outcomes. Patients who receive CAR T-cell therapy are also profoundly immunosuppressed and often cytopenic, which is caused by a multitude of patient- and treatment-related factors. Thus, infection-related complications are also common in this group. Indeed, up to one third of patients will suffer a serious bacterial infection in the first 30 days after therapy. Viral respiratory tract infection appears to be the most common during the late phase and can be severe; one patient has died of influenza A infection. Fungal infection and cytomegalovirus (CMV) reactivation appear to be uncommon. Although institutional guidelines on infection-prevention strategies are available, there is a dearth of evidence to support their approach. Future research needs to target important unanswered questions that remain in this patient population in order to improve their short- and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.